Zinlirvimab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameZinlirvimab
Drug Alias Nameneutralizing monoclonal antibodyneutralizing mAb targeting V3 glycan10-107410-1074-LSGS-2872
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionHIV envelope protein gp120 modulators
TargetsHIV envelope protein gp120
Therapy Area/IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaBotswanaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Rockefeller University
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncNational Institute Of Allergy And Infectious Diseases (Niaid)The Rockefeller University
Inactive CompaniesN/A
Active IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A